Altimmune Announces Publication of IMPACT Phase 2b 48-Week Data in MASH in The Lancet Gastroenterology & HepatologyGlobeNewsWire • Thursday
Altimmune Presents Positive Late-Breaking Pemvidutide Data at AASLD The Liver Meeting® 2026 in Patients with Alcohol Use DisorderGlobeNewsWire • Monday
Altimmune Announces Data from RECLAIM Phase 2 Trial of Pemvidutide in Alcohol Use Disorder Selected as Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2026GlobeNewsWire • 11/05/26
Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026GlobeNewsWire • 11/05/26
Altimmune Appoints Peter Greenleaf and Alex Howarth, Two Leading Biotech Executives, to Board of Directors to Support Its Strategic EvolutionGlobeNewsWire • 10/27/26
Altimmune to Present New Data on Pemvidutide in Serious Liver Diseases at AASLD The Liver Meeting® 2026GlobeNewsWire • 10/19/26
Altimmune to Participate in the Wells Fargo 21st Annual Healthcare ConferenceGlobeNewsWire • 09/03/26
Altimmune's Phase III MASH Study Puts 2029 Data in Investor FocusZacks Investment Research • 08/19/26
Is Altimmune Worth Buying as Cash Rises but Execution Risks Linger?Zacks Investment Research • 08/19/26
ALT's Q2 Loss Narrower Than Expected, Pemvidutide's Studies in FocusZacks Investment Research • 08/13/26
Altimmune Announces Second Quarter 2026 Financial Results and Business UpdateGlobeNewsWire • 08/12/26
Altimmune to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026GlobeNewsWire • 08/05/26
Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASHGlobeNewsWire • 08/03/26
Altimmune, Inc. (ALT) Discusses Topline Results of RECLAIM Phase II Trial of Pemvidutide in Alcohol Use Disorder TranscriptSeeking Alpha • 07/28/26